Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07127822) titled 'Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University
Condition:
Gastric / Gastroesophageal Junction Adenocarcinoma
MSI-H Cancer
Intervention:
Drug: Iparomlimab and Tuvonralimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2025
Target Sample Size: 106
Countries of Recruitment:
China
To know more, visit https://clin...